Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eisai, Pfizer Gain Approval for Higher-Dose Aricept | Contract Pharma

What are you searching for?

Sign in

Eisai, Pfizer Gain Approval for Higher-Dose Aricept

Eisai and Pfizer received approval from the FDA for a new once-daily, higher-dose Aricept (donepezil HCl) 23 mg tablet for the treatment of moderate-to-severe Alzheimer’s disease (AD).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eisai and Pfizer received approval from the FDA for a new once-daily, higher-dose Aricept (donepezil HCl) 23 mg tablet for the treatment of moderate-to-severe Alzheimer’s disease (AD). Aricept 23 mg tablet offers another dosing option for patients with moderate-to-severe AD.

The approval is based on data from a large head-to-head study of Aricept 23 mg tablet versus Aricept 10 mg tablet in more than 1,400 patients with moderate-to-severe AD. Aricept 23 mg tablet demonstrated a statistically significant improvement in cognition, but did not achieve statistically significant improvement in global function, as compared to Aricept 10 mg tablet.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters